Skip to content

Kelly C. Lee

3 papers in the library · 26 citations · publishing 2017-2020

Papers

Sort Most recent Most cited

Safety of Repeated Administration of Parenteral Ketamine for Depression

Pharmaceuticals July 13, 2020 David Feifel, David Dadiomov, Kelly C. Lee

The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to...

Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.

Journal of Affective Disorders October 15, 2017 David Feifel, Benjamin Malcolm, Danielle Boggie et al.

Recent studies demonstrating a rapid, robust improvement in treatment resistant depression (TRD) following a single sub-anesthetic infusion of ketamine have generated much excitement. However, these studies are limited in their generalizability to the broader TRD population due to their subject exclusion criteria which typically limit psychiatric comorbidity, concurrent medication, and level of...

Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Mental Health Clinician 2017 Benjamin Malcolm, Kelly C. Lee 26 citations

Abstract Ayahuasca is a traditional psychoactive sacrament that's been used in Amazonian shamanic rituals for hundreds of years. Ayahuasca is notorious for its psychedelic properties produced from the combination of monoamine oxidase inhibitors (MAOIs) found in the Banisteriopsis caapi vine and N-N-dimethyltryptamine from Psychotria viridis or Diplopterys cabrerana. Recently, ritual use of...

DOI: 10.9740/mhc.2017.01.039 (opens in new tab) Full text (opens in new tab) Ayahuasca Hallucinogen Mental illness Psychoactive substance +1